Immunovia facility expansion
Today, on World Pancreatic Cancer Day November 15 2018, we are delighted to share with you some exciting news about Immunovia. The company is growing and is expanding its facility in Lund, Sweden.
In preparation for commercialising IMMray™ PanCan-d for the early detection of pancreatic cancer, Immunovia has completed the expansion of its production and sample testing facilities, IMMray™ Dx Laboratory, at its headquarter site in Lund, Sweden.
These new facilities expand Immunovia’s footprint by 500 m2 providing the capability to produce slides to meet both the demands for the large prospective studies needed for reimbursement as well as for the launch of IMMray™ PanCan-d the latter part of 2019.
In parallel, the completion of the IMMray™ Dx Laboratory will enable patient samples from Europe and other countries around the world to be tested on site with IMMray™ PanCan-d.
US patient samples will be tested at Immunovia’s subsidiary in Marlborough, Massachusetts that opened in June 28, 2017 (Press Release).
For more information about World Pancreatic Cancer Day, please visit: https://www.worldpancreaticcancerday.se/